Building on their long-standing research collaboration, Numab Therapeutics and Japanese Ono Pharmaceuticals have inked a development and license agreement for their joint multispecific antibody candidate. The new deal brings Numab CHF 258 million in research funding, upfront and milestone payments.
Numab Therapeutics is creating multi-specific antibodies based on proprietary MATCH technology platform. Since 2017, Numab and its partner Ono Pharmaceutical Co., Ltd., have been collaborating to identify a multi-specific antibody candidate for development in immuno-oncology. Ono has now exercised its option to enter into a development and license agreement for a multispecific antibody candidate. Under the terms of the license agreement, Ono acquires intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-oncology target. In consideration for the discovery work and the license, Numab will receive up to CHF 258 million in research funding, upfront and milestone payments plus tiered single to double-digit royalties on future sales.
“We are proud to have advanced this novel multispecific antibody candidate against a new and very challenging immuno-oncology target to this milestone,” said David Urech, Founder and Chief Executive Officer of Numab. “The licensing of the asset is an affirmation of our platform’s ability to create novel and unique pharmacology. We look forward to our continued partnership with Ono as we have been further collaborating on our shared mission of developing next-generation immuno-oncology therapeutics for patients with cancer.”
“We hope that the program candidate generated through our work with Numab will become a therapeutic option for patients with cancer who may benefit from this new treatment modality,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical. “Through the synergy between Numab’s multispecific antibody platform and Ono’s deep immuno-oncology expertise, we are continuously committed to fueling our diverse drug discovery efforts to advance our immuno-oncology pipeline.”
In March 2020, Numab and Ono expanded their alliance by executing a second research and option agreement to discover and develop a multispecific antibody drug candidate for the treatment of various cancers.
(Press release / RAN)
Please login or sign up to comment.
Commenting guidelines